Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 6/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CHRND | Q07001 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905208 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL401138 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL676026 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL31375263 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7836790 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3217337 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7480026 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7464746 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL905236 | 0.89 | CHRNA3 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL905201 | 0.89 | CHRNA3 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | disclosed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | disclosed |
| US-20240159774-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-16 | — | — | US | disclosed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | disclosed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | CASR, ORAI1, TRPC3 | CHRNB2 289/4885CHRNA4 459/4885CHRNA3 319/4885 |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | EYA3, RB1, ALDH1A2 | CHRNB2 63/4885CHRNA4 353/4885CHRNA3 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.